Literature DB >> 34295555

Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.

Zengbao Lin1, Huiqin Bian1, Chaoyuan Chen1, Wenling Chen2, Qiong Li3.   

Abstract

BACKGROUND: Gastric cancer is a common malignant tumor. The aim of the present study was to analyze the application value of serum pepsinogen (PG), carbohydrate antigen 72-4 (CA72-4), and gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.
METHODS: In total, 122 patients with gastric cancer treated in our hospital from January 2018 to January 2021 were selected as the gastric cancer group and subdivided into the early gastric cancer (group A) and advanced gastric cancer (group B) groups. Sixty-five patients with benign gastric disease treated in the same hospital during the same period were selected as the control group, and 122 healthy people who underwent physical examination during the same period were allocated to the control group. The differences in the levels of G-17, PGI, PGII, PGI/PGII, and CA72-4 were compared; receiver-operating characteristic curves were drawn; and the efficacy of different factors in the diagnosis of early gastric cancer was calculated.
RESULTS: G-17, PGI, and PGI/PGII levels in the gastric cancer group were significantly lower than those in the healthy group, and CA72-4 was significantly higher than that in the healthy group (P<0.05), but there was no significant difference in PGII between the 2 groups (P>0.05). G-17, PGI, and PGI/PGII levels in groups A and B were significantly lower than those in the control group. CA72-4 in groups A and B was significantly higher than that of the control group, and was highest in group B (P<0.05). The areas under the curve (AUC) of G-17, PGI, PGI/PGII, and CA72-4 were 0.671, 0.726, 0.769, and 0.602, respectively, and the AUC of combined detection was 0.883, which was significantly higher than that of single detection.
CONCLUSIONS: Serum PG, CA72-4 combined with G-17 detection has high sensitivity and specificity in the screening and diagnosis of early gastric cancer, and has high clinical application value. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Serum pepsinogen (serum PG); carbohydrate antigen 72-4 (CA72-4); early gastric cancer; gastric cancer screening; gastrin-17 (G-17)

Year:  2021        PMID: 34295555      PMCID: PMC8261308          DOI: 10.21037/jgo-21-254

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  20 in total

Review 1.  Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.

Authors:  R M Zagari; S Rabitti; D C Greenwood; L H Eusebi; A Vestito; F Bazzoli
Journal:  Aliment Pharmacol Ther       Date:  2017-08-07       Impact factor: 8.171

2.  Assessment of serum aflatoxin B1 levels in neonatal jaundice with glucose-6-phosphate dehydrogenase deficiency: a preliminary study.

Authors:  Nermin Raafat; Wafaa A Emam; Amal F Gharib; Ola E Nafea; Marwa Zakaria
Journal:  Mycotoxin Res       Date:  2021-01-11       Impact factor: 3.833

3.  Association of dietary acid load with serum bicarbonate in chronic kidney disease (CKD) patients.

Authors:  Larissa Rodrigues Neto Angeloco; Gabriela Cristina Arces de Souza; Elen Almeida Romão; Lynda Frassetto; Paula Garcia Chiarello
Journal:  Eur J Clin Nutr       Date:  2020-08       Impact factor: 4.016

4.  Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.

Authors:  Kyung Hwa Shin; Hyung Hoi Kim; Byung Su Kwon; Dong Soo Suh; Jong Kil Joo; Ki Hyung Kim
Journal:  Ann Lab Med       Date:  2020-01       Impact factor: 3.464

5.  Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations.

Authors:  Muhammad Miftahussurur; Langgeng Agung Waskito; Hafeza Aftab; Ratha-Korn Vilaichone; Phawinee Subsomwong; Iswan Abbas Nusi; Ari Fahrial Syam; Thawee Ratanachu-Ek; Dalla Doohan; Gontar Siregar; Yudith Annisa Ayu Rezkitha; Kartika Afrida Fauzia; Varocha Mahachai; Yoshio Yamaoka
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

6.  EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

Authors:  Daphne S Bakker; Lieneke F M Ariens; Barbara Giovannone; DirkJan Hijnen; Eveline M Delemarre; Edward Knol; Stefan Nierkens; Marjolein S de Bruin-Weller; Judith L Thijs; Julia Drylewicz
Journal:  Allergy       Date:  2020-07-24       Impact factor: 13.146

7.  Efficacy of toluidine blue in the diagnosis and screening of oral cancer and pre-cancer: A systematic review and meta-analysis.

Authors:  Do Hyun Kim; Eun A Song; Sung Won Kim; Se Hwan Hwang
Journal:  Clin Otolaryngol       Date:  2020-11-12       Impact factor: 2.597

8.  Cancer/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers.

Authors:  Akiko Shida; Takashi Fukuyama; Nobue Futawatari; Haruki Ohmiya; Yoshinobu Ichiki; Tetsuro Yamashita; Yatsushi Nishi; Noritada Kobayashi; Hitoshi Yamazaki; Masahiko Watanabe; Yoshihito Takahashi
Journal:  World J Gastroenterol       Date:  2020-01-28       Impact factor: 5.742

9.  Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer.

Authors:  Yaping Wang; Zhiyong Zhu; Zhilan Liu; Zhen Zhao; Xiaohong Xue; Xiaolin Li; Pingying Li; Guanghong Rong; Yingcai Ma
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

View more
  2 in total

Review 1.  Potential Non-invasive Biomarkers of Helicobacter pylori-Associated Gastric Cancer.

Authors:  Fatima Boubrik; Ahmed Belmouden; Nadia El Kadmiri
Journal:  J Gastrointest Cancer       Date:  2021-11-12

2.  Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer.

Authors:  Zhen Wang; Tang-Ming Mo; Lei Tian; Jun-Qiang Chen
Journal:  Int J Gen Med       Date:  2021-11-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.